Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma

The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression-free survival (PFS) in patients with metastatic melanoma compared with ipilimumab alone. The median PFS in the group treated with the combination therapy was 11.5 months compared with 6.9 months in the nivolumab monotherapy group and 2.9 months in the ipilimumab monotherapy group.

Presented by Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at ASCO 2015.